ALT
Altimmune, Inc.
$2.12
-2.30%
2026-10-23
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Key Fundamentals
Forward P/E
-4.58
EPS (TTM)
$-0.76
ROE
-28.9%
Revenue Growth (YoY)
420.0%
Profit Margin
0.0%
Debt/Equity
7.60
Price/Book
1.26
Beta
0.18
Market Cap
$595.2M
Avg Volume (10D)
4.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$3.55
60D Low
$2.06
Avg Volume
4.1M
Latest Close
$2.12
Get breakout alerts for ALT
Sign up for Breakout Scanner to receive daily notifications when ALT triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Altimmune, Inc. (ALT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ALT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ALT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.